Search
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigational[L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.
Categories: Hormonal Contraceptives for Systemic UseEconazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseRepinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Semzuvolimab
go.drugbank.com/drugs/DB18920InvestigationalSemzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
AAV8-RK-RetGC
go.drugbank.com/drugs/DB32389ExperimentalAAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.
Synonyms: AAV8-RK-RetGCCYNK-101
go.drugbank.com/drugs/DB18637InvestigationalCYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Perflubron
go.drugbank.com/drugs/DB05791InvestigationalPerflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Categories: Compounds used in a research, industrial, or household settingZidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.